With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in … Continue reading Leqembi Vs. Kisunla: An Alzheimer’s Drug Point-by-Point Comparison